NCT02508337View on ClinicalTrials.gov

Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain

PHASE3CompletedINTERVENTIONAL
Enrollment

309

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

January 31, 2016

Study Completion Date

March 31, 2016

Conditions
InflammationPainCataract
Interventions
DRUG

XG-102

Comparison of XG-102 versus placebo for the treatment of ocular inflammation and pain associated with cataract surgery

DRUG

Placebo

Comparison of XG-102 versus placebo for the treatment of ocular inflammation and pain associated with cataract surgery

Trial Locations (1)

01810

Ora, Andover

All Listed Sponsors
lead

Xigen SA

INDUSTRY

NCT02508337 - Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain | Biotech Hunter | Biotech Hunter